
Blueprint Medicines Appoints Habib Dable to its Board of Directors



Blueprint Medicines Corporation announced the appointment of Habib Dable to its board of directors. Mr. Dable, who was Chief Executive Officer of Acceleron Pharma from 2016 to 2021, brings nearly 30 years of experience in strategic leadership, commercial growth and organizational scale across global pharmaceutical and emerging biotechnology companies.

"Habib's experience leading global, complex organizations will be incredibly valuable as Blueprint Medicines drives our next phase of transformational growth," said Kate Haviland, Chief Executive Officer. "We are thrilled to welcome his significant expertise and perspective to our board."

"Blueprint Medicines has an impressive track record for a company of its size and age; even more impressive are the potential opportunities that lie ahead across development and commercialization," said Mr. Dable. "I look forward to working with Blueprint's high caliber team to execute on these opportunities and continue bringing the promise of precision medicine to broad patient populations."

Mr. Dable joins Blueprint Medicines with significant leadership, growth and commercial experience gained during nearly 30 years in the biopharmaceutical industry. Most recently, as CEO at Acceleron, Mr. Dable generated more than \$10 billion in shareholder value over his 5-year tenure as CEO before successfully transitioning to Merck following its acquisition. Prior to joining Acceleron in 2016, Mr. Dable spent 22 years at Bayer AG. During his tenure at Bayer, Mr. Dable held positions of increasing responsibility and geographic footprint, including President of U.S. Pharmaceuticals; Executive Vice President, Global Head Specialty Medicine; Vice President, Ophthalmology; Global Launch Team Head, EYLEA®; Global Head, Neurology and Ophthalmology; and Vice President, Regional Head, Hematology and Cardiology. Recently, Mr. Dable served on the Board of Directors of the Biotechnology Innovation Organization (BIO). Mr. Dable received a B.B.A. in Marketing and Finance and his M.B.A. from the University of New Brunswick.

Source: [Blueprint Medicines](#)

Published on : Thu, 23 Jun 2022